Search

Displaying results 4261 - 4270 of 5261 in total
  1. Drug

    PIK3CA

    go.drugbank.com/drugs/DB14954
    Investigational

    PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).

  2. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.

  3. Drug

    Hypoxanthine

    go.drugbank.com/drugs/DB04076
    Investigational

    Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.

  4. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

  5. Drug

    LY3884961

    go.drugbank.com/drugs/DB17070
    Investigational

    LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]

  6. Drug

    MBP-091

    go.drugbank.com/drugs/DB17741
    Experimental

    MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]

  7. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  8. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    These amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263].

  9. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.

  10. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.